160 related articles for article (PubMed ID: 32577584)
1. Scleral fixation of fluocinolone acetonide implant.
Tabandeh H; Rezaei K
Am J Ophthalmol Case Rep; 2020 Sep; 19():100775. PubMed ID: 32577584
[TBL] [Abstract][Full Text] [Related]
2. Anterior migration of intravitreal fluocinolone acetonide (Iluvien®) implant in a pseudophakic eye with intact posterior capsule.
Alzaabi M; Taguri AH; Elbarky A
Am J Ophthalmol Case Rep; 2020 Dec; 20():100922. PubMed ID: 32995665
[TBL] [Abstract][Full Text] [Related]
3. Challenging Clinical Cases - A Walk Through Supplemental Therapy with Intravitreal Ranibizumab Therapy Following Treatment of Diabetic Macular Edema with the 0.19 mg Fluocinolone Acetonide Implant (ILUVIEN
Pessoa B; Melo-Beirão J; Meireles A; Menéres P
Int Med Case Rep J; 2020; 13():437-448. PubMed ID: 32982484
[TBL] [Abstract][Full Text] [Related]
4. Early adoption of the fluocinolone acetonide (FAc) intravitreal implant in patients with persistent or recurrent diabetic macular edema (DME).
McCluskey JD; Kaufman PL; Wynne K; Lewis G
Int Med Case Rep J; 2019; 12():93-102. PubMed ID: 31114396
[No Abstract] [Full Text] [Related]
5. Anterior Chamber Dislocation of Dexamethasone Implant in the Presence of Carlevale Sutureless Scleral Fixation Intraocular Lens.
Stavrakas P; Gartaganis P; Totou S; Chalkiadaki E; Manousakis E; Karmiris E
Case Rep Ophthalmol; 2023; 14(1):229-233. PubMed ID: 37383169
[TBL] [Abstract][Full Text] [Related]
6. A Novel Technique for Repositioning of a Migrated ILUVIEN(®) (Fluocinolone Acetonide) Implant into the Anterior Chamber.
El-Ghrably IA; Saad A; Dinah C
Ophthalmol Ther; 2015 Dec; 4(2):129-33. PubMed ID: 26199036
[TBL] [Abstract][Full Text] [Related]
7. Fluocinolone Acetonide Intravitreal Implant 190 μg (ILUVIEN®) in Vitrectomized versus Nonvitrectomized Eyes for the Treatment of Chronic Diabetic Macular Edema.
Pessoa B; Coelho J; Correia N; Ferreira N; Beirão M; Meireles A
Ophthalmic Res; 2018; 59(2):68-75. PubMed ID: 29248913
[TBL] [Abstract][Full Text] [Related]
8. Scleral Fixation of the Fluocinolone Acetonide Implant in Eyes with Severe Iris-Lens Diaphragm Disruption and Recalcitrant CME: The Fluocinolone-Loop-Anchoring Technique (FLAT).
Herold TR; Liegl R; Koenig S; Almarzooqi A; Priglinger SG; Wolf A
Ophthalmol Ther; 2020 Mar; 9(1):175-179. PubMed ID: 32056140
[TBL] [Abstract][Full Text] [Related]
9. Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment.
Rehak M; Busch C; Unterlauft JD; Jochmann C; Wiedemann P
Acta Diabetol; 2020 Apr; 57(4):469-478. PubMed ID: 31749051
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal Fluocinolone Acetonide Implant (FAc, 0.19 mg, ILUVIEN®) in the Treatment of Patients with Recurrent Cystoid Macular Edema After Pars Plana Vitrectomy.
Lima-Fontes M; Leuzinger-Dias M; Barros-Pereira R; Fernandes V; Falcão M; Falcão-Reis F; Rocha-Sousa A; Alves-Faria P
Ophthalmol Ther; 2023 Feb; 12(1):377-388. PubMed ID: 36417092
[TBL] [Abstract][Full Text] [Related]
11. A novel intravitreal fluocinolone acetonide implant (Iluvien(®)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series.
Schmit-Eilenberger VK
Clin Ophthalmol; 2015; 9():801-11. PubMed ID: 25999689
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy.
Meireles A; Goldsmith C; El-Ghrably I; Erginay A; Habib M; Pessoa B; Coelho J; Patel T; Tadayoni R; Massin P; Atorf J; Augustin AJ
Eye (Lond); 2017 May; 31(5):684-690. PubMed ID: 28085139
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7 mg dexamethasone implant in patients with diabetic macular edema.
Singh P; Chedid A; Deuchler SK; Kohnen T; Müller M; Koch FH
Int Med Case Rep J; 2018; 11():265-269. PubMed ID: 30410411
[TBL] [Abstract][Full Text] [Related]
14. Diabetic macular edema outcomes in eyes treated with fluocinolone acetonide 0.2 µg/d intravitreal implant: real-world UK experience.
El-Ghrably I; Steel DHW; Habib M; Vaideanu-Collins D; Manvikar S; Hillier RJ
Eur J Ophthalmol; 2017 May; 27(3):357-362. PubMed ID: 28165610
[TBL] [Abstract][Full Text] [Related]
15. Comparison of data characterizing the clinical effectiveness of the fluocinolone intravitreal implant (ILUVIEN) in patients with diabetic macular edema from the real world, non-interventional ICE-UK study and the FAME randomized controlled trials.
Holden SE; Kapik B; Beiderbeck AB; Currie CJ
Curr Med Res Opin; 2019 Jul; 35(7):1165-1176. PubMed ID: 30569759
[No Abstract] [Full Text] [Related]
16. Persistent or Recurrent Diabetic Macular Edema After Fluocinolone Acetonide 0.19 mg Implant: Risk Factors and Management.
Cicinelli MV; Rabiolo A; Zollet P; Capone L; Lattanzio R; Bandello F
Am J Ophthalmol; 2020 Jul; 215():14-24. PubMed ID: 32209341
[TBL] [Abstract][Full Text] [Related]
17. PARS PLANA VITRECTOMY WITH ANTERIOR CHAMBER VERSUS GORE-TEX SUTURED POSTERIOR CHAMBER INTRAOCULAR LENS PLACEMENT: Long-Term Outcomes.
Khan MA; Gupta OP; Pendi K; Chiang A; Vander J; Regillo CD; Hsu J
Retina; 2019 May; 39(5):860-866. PubMed ID: 29346243
[TBL] [Abstract][Full Text] [Related]
18. Alternative technique for the injection of fluocinolone acetonide (FAc) intravitreal implant (Iluvien
Diago T; Fau SG; Roca JM
Eur J Ophthalmol; 2023 May; 33(3):1501-1505. PubMed ID: 36632008
[TBL] [Abstract][Full Text] [Related]
19. Optical Coherence Tomography Biomarkers: Vitreous Status Influence in Outcomes for Diabetic Macular Edema Therapy with 0.19-mg Fluocinolone Acetonide Implant.
Pessoa B; Ferreira A; Leite J; Figueira J; Meireles A; Beirão JM
Ophthalmic Res; 2021; 64(4):639-647. PubMed ID: 33601389
[TBL] [Abstract][Full Text] [Related]
20. A New Approach for Diabetic Macular Edema Treatment: review of clinical practice results with 0.19 mg fluocinolone acetonide intravitreal implant including vitrectomized eyes.
Estebainha R; Goldhardt R; Falcão M
Curr Ophthalmol Rep; 2020 Mar; 8(1):1-10. PubMed ID: 32346496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
